It took almost exactly 11 months for FDA to finalize its decision to pull Roche /Genentech Inc. 's Avastin (bevacizumab) metastatic breast cancer indication.
Like everything else in the first-of-its-kind “streamlined withdrawal” process, that sets a precedent.